Please assess the completion status of the following clinical trial:

Trial Title: Gypenosides Treatment for Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Male and female Chinese patients aged ≥18 to ≤60 years~2. Patients with a first episode of optic neuritis in the eye of interest~3. First symptoms of optic neuritis ≤28 days prior to the first administration of investigational product~4. Best corrected visual acuity in the eye of interest ≤0.8~Exclusion criteria~1. Pre-existing multiple sclerosis MS or NMO~2. Refractive media opacity~3. Hyperopia \>5 diopters, myopia \<-5 diopters, or astigmatism \>3 diopters~4. Active tuberculosis, hepatitis, renal insufficiency, uncontrolled hypertension, diabetes mellitus, infection with HIV or syphilis, or any other conditions potentially interfering treatment trial~5. Other autoimmune diseases (systemic lupus erythematosus, rheumatoid arthritis, etc)~6. Existing other retina or optic nerve diseases~7. Pregnant or females who plan to be pregnant during study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Gypenosides (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).